Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233110 | 1.00 | CYP2D6 (0.43) | CYP2D6ALDH1A1TACR1TACR3NR3C1 | |
| SCHEMBL7617784 | 0.91 | NR3C1 (0.44) | CYP2D6ALDH1A1NR3C1KDM4EGAA | |
| SCHEMBL1618300 | 0.84 | NR3C1 (0.48) | CYP2D6ALDH1A1TACR1TACR3NR3C1 | |
| SCHEMBL5265862 | 0.81 | CYP2D6 (0.44) | CYP2D6ALDH1A1TACR1TACR3NR3C1 | |
| SCHEMBL5265856 | 0.81 | CYP2D6 (0.44) | CYP2D6ALDH1A1TACR1TACR3NR3C1 | |
| SCHEMBL5225914 | 0.80 | STS (0.40) | TACR1TACR3KDM4EPKM | |
| SCHEMBL5225910 | 0.80 | STS (0.40) | TACR1TACR3KDM4EPKM | |
| SCHEMBL2237372 | 0.79 | NR3C1 (0.45) | CYP2D6ALDH1A1TACR1TACR3NR3C1 | |
| SCHEMBL21465773 | 0.77 | CYP2D6 (0.46) | CYP2D6ALDH1A1NR3C1KDM4EGAA | |
| SCHEMBL12487550 | 0.73 | ABL1 (0.45) | CYP2D6ALDH1A1NR3C1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001970-B1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6953791-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951850-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6924280-B2 | Dipeptide derivatives | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-RE38524-E1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2004-06-01 | — | — | US | disclosed |
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | CARPINO PHILIP ALBERT (US) | 2004-01-15 | — | — | US | disclosed |
| US-20040006063-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030216399-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2003-11-20 | — | — | US | disclosed |
| US-6432945-B1 | Dipeptide derivatives | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6429313-B2 | Dipeptide derivatives | PFIZER INC. | 2002-08-06 | — | — | US | disclosed |
| US-20020065284-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020042415-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020002165-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-01-03 | — | — | US | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | GHSR, GHRHR, GIPR | CYP2D6 1161/4885ALDH1A1 3158/4885TACR1 255/4885 |
| US-20020042415-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | CYP2D6 1702/4885ALDH1A1 3934/4885TACR1 218/4885 |
| US-20020002165-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | CYP2D6 1702/4885ALDH1A1 3934/4885TACR1 218/4885 |
| US-20040006063-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | CYP2D6 1103/4885ALDH1A1 3126/4885TACR1 176/4885 |
| US-20030216399-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | CYP2D6 1702/4885ALDH1A1 3934/4885TACR1 218/4885 |
| US-20020065284-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | CYP2D6 1702/4885ALDH1A1 3934/4885TACR1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.